FDA seeks more time to review Takeda's Actos-alogliptin combo

07/23/2009 | Bloomberg

Takeda Pharmaceutical said the FDA moved to Sept. 4 its deadline to decide whether to approve a drug that blends diabetes drugs Actos and alogliptin. Review of the fixed-dose combination is separate from Takeda's application for alogliptin, which failed to gain FDA approval last month.

View Full Article in:

Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
In house Compliance Officer
Confidential
Pompano Beach, FL
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC